David Saul is a co-founder and CEO of Titan Biosciences, where he is building gene therapies for genetic heart disease. Titan is developing an AAV delivered CRISPR activation approach for dilated cardiomyopathy caused by TTN truncating variants. David previously worked at Regel Therapeutics and trained in the Seidman Lab at Harvard Medical School, where he studied titin biology and cardiomyopathies. His experience includes CRISPR cell line engineering, iPSC based disease models, and translational gene therapy development.